JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
122.91
-0.81 (-0.65%)
At close: 4:02PM EDT

123.00 +0.09 (0.07%)
After hours: 7:33PM EDT

Stock chart is not supported by your current browser
Previous Close123.72
Open123.80
Bid122.76 x 3100
Ask123.08 x 1800
Day's Range122.76 - 124.24
52 Week Range121.28 - 148.32
Volume7,171,067
Avg. Volume6,740,350
Market Cap329.663B
Beta0.59
PE Ratio (TTM)259.30
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.36 (2.57%)
Ex-Dividend Date2018-02-26
1y Target EstN/A
Trade prices are not sourced from all markets
  • MarketWatch5 hours ago

    Merck’s experimental and unlicensed Ebola vaccine is being used in latest outbreak

    The World Health Organization has started to vaccinate thousands of people considered at high risk of contacting the infectious and often-deadly disease Ebola in the Democratic Republic of Congo. The WHO said Monday it is working with NGOs and community leaders to administer an experimental vaccine that was studied in a trial in Guinea in 2015, but has not yet been used to contain a major outbreak. Most are in a remote town, but there are four confirmed cases in Mbandaka, the provincial capital which has a population of more than 1 million people.

  • JNJ’s Baby Care Line Set for Relaunch to Stimulate Falling Sales
    Market Realist6 hours ago

    JNJ’s Baby Care Line Set for Relaunch to Stimulate Falling Sales

    Thus, the company has announced its plans to make some changes in its baby care product line and is set for a relaunch with a target of more naturally sourced products with recyclable packaging. The redesigned line is expected to launch in August. Johnson & Johnson is planning an end-to-end relaunch. Johnson & Johnson recognizes the need to make certain fundamental changes to its products after witnessing declining sales from its leading range of baby care products.

  • How Are Tesaro’s Valuations and Cash Flows?
    Market Realist7 hours ago

    How Are Tesaro’s Valuations and Cash Flows?

    Tesaro used $147.6 million in operating activities in the first quarter—compared to $114.6 million in the first quarter of 2017. The company used $1.6 million in investing activities in the first quarter—compared to $1.8 million in the first quarter of 2017. The expense was mainly for purchasing property and equipment related to Tesaro expanding leased premises at its headquarters.

  • Wall Street Sees Upside of More than 17% for JNJ in the Next Year
    Market Realist9 hours ago

    Wall Street Sees Upside of More than 17% for JNJ in the Next Year

    Over the last few quarters, Johnson & Johnson (JNJ) has seen a number of factors affecting investor sentiments surrounding its stock. The company, however, posted strong results for the first quarter on April 17, exceeding analysts’ estimates. In this article, we’ll take a look at analysts’ recommendations on JNJ for the next 12 months.

  • Gauging the Upside Potential of Vertex Pharmaceuticals Stock
    Market Realist10 hours ago

    Gauging the Upside Potential of Vertex Pharmaceuticals Stock

    Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies for treating cystic fibrosis (or CF) and advancing research and development programs for other diseases. Of the 25 analysts covering Vertex Pharmaceuticals in May, 21 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.76 with a target price of $191.39, implying an upside of 22.6% over its closing price of $156.16 on May 16. Of the 26 analysts covering Gilead Sciences (GILD) in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.15 with a target price of $85.81.

  • Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval
    Zacks11 hours ago

    Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval

    Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.

  • Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018
    Market Realist11 hours ago

    Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018

    Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.

  • Chinese investors lead another monster round into this early cancer detection company
    American City Business Journals23 hours ago

    Chinese investors lead another monster round into this early cancer detection company

    The Menlo Park company had already raised $1.2 billion; now it's adding $300 million, mainly from Chinese investors, as it aims to develop a simple blood test to discover cancers early.

  • TheStreet.comyesterday

    How to Play the Long Side of Johnson & Johnson

    In this daily bar chart of JNJ, below, we can see that prices for JNJ have been under selling pressure since late January. In the bottom panel is the 12-day price momentum study which shows a pattern of rising lows from February to March to April. In this weekly bar chart of JNJ, below, we have a mixed picture.

  • InvestorPlaceyesterday

    It’s Not as Bad as It Looks for Johnson & Johnson Stock

    It’s been a bumpy ride so far this year for pharmaceutical giant Johnson & Johnson (NYSE:JNJ). Johnson & Johnson has been weighed down by poor sentiment in the healthcare space, legal troubles and worries about further government interference in the industry. One such concern has been Johnson & Johnson’s Baby Care unit.

  • InvestorPlaceyesterday

    7 ‘Blue-Chip Stocks’ That Aren’t Blue Chips at All

    A lot of large-cap familiar names are still called “blue-chip stock” when they are nothing of the kind. If you can’t rid the term “blue-chip stock” from your lexicon, then it should at least apply to a whole new stream of companies. “Blue-chip stock” used to refer to companies that were constantly growing earnings in the high single-digits or more in terms of percentage, had a fortress balance sheet and were constantly innovating.

  • 3 Days Left To Cash In On Johnson & Johnson (NYSE:JNJ) Dividend, Is It Worth Buying?
    Simply Wall St.yesterday

    3 Days Left To Cash In On Johnson & Johnson (NYSE:JNJ) Dividend, Is It Worth Buying?

    Have you been keeping an eye on Johnson & Johnson’s (NYSE:JNJ) upcoming dividend of $0.9 per share payable on the 12 June 2018? Then you only have 3 days leftRead More...

  • Benzingayesterday

    The Week Ahead In Biotech: PDUFA Dates, IPOs And More

    Some M&A activity , earnings news flow and clinical trial outcomes helped the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) preserve gains this week. As the earnings season winds down, here're ...

  • A Look into Roche Holding’s Performance in Q1 2018
    Market Realistyesterday

    A Look into Roche Holding’s Performance in Q1 2018

    In the first quarter, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in the first quarter of 2017, which reflected ~5.0% growth on a YoY (year-over-year) basis.

  • Reuters2 days ago

    Congo to begin Ebola vaccinations on Monday

    H ealth workers in Democratic Republic of Congo will begin a vaccination campaign on Monday aimed at containing an outbreak of the deadly Ebola virus, a spokeswoman for the health ministry said. Jessica Ilunga said 4,000 doses of vaccine were shipped on Saturday to Mbandaka, which last week registered the first cases in an urban area since the latest flare-up of the disease was announced earlier this month.

  • Reuters4 days ago

    Congo's Ebola not an international emergency, can be controlled -WHO

    GENEVA/KINSHASA, May 18 (Reuters) - The Ebola outbreak in Democratic Republic of Congo can be brought under control and is not an international public health emergency, experts advising the World Health Organization said on Friday. Earlier in the day the WHO had said the first confirmation of Ebola in Mbandaka, a city of about 1.5 million people, had prompted it to declare a "very high" public health risk to the country and a "high" risk to the region.

  • Eli Lilly’s Valuation on May 17
    Market Realist4 days ago

    Eli Lilly’s Valuation on May 17

    Eli Lilly (LLY) reported EPS of $1.34 and revenues of $5.7 billion in the first quarter. Both results surpassed Wall Street analysts’ estimates.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks4 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • Reuters4 days ago

    Johnson & Johnson scraps Alzheimer's trials on safety concerns

    Johnson and Johnson said it would stop mid-stage trials testing its experimental Alzheimer's drug after observing safety issues, the latest drugmaker to abandon developing treatments for the memory-robbing disease. Some trial participants showed serious elevations of liver enzymes and the company concluded that the benefit-risk ratio offered by the drug, atabecestat, no longer supported its development, said http://www.janssen.com/update-janssens-bace-inhibitor-program Janssen, a unit of Johnson and Johnson. Atabecestat belongs to a class of experimental Alzheimer's drugs called BACE inhibitors that block an enzyme involved in the production of a protein that creates brain plaques, which are considered a major cause for the disease.

  • US birth rates hit record low and diaper, baby bottle companies are feeling the pinch
    CNBC4 days ago

    US birth rates hit record low and diaper, baby bottle companies are feeling the pinch

    As would-be parents push back parenthood and birth rates continue to decline companies that provide baby products are feeling the pinch.

  • Investopedia5 days ago

    Why J&J's Stock May Plunge 10%

    Johnson & Johnson ( JNJ) shares may drop by about 10% based on an analysis of the technical chart. Should shares of the stock fall an additional 10%, it would mean Johnson and Johnson would have dropped by nearly 25% from its intraday high of around $148 on January 22. The technical setup continues to be negative in the stock, and it appears shares could fall from roughly $124.25 to about $111.33, a drop of 10.4%.

  • Benzinga5 days ago

    How To Get Quality In The Core

    Many exchange-traded funds that are viewed as “core” holdings are cap-weighted. Core funds that emphasize individual investment factors usually focus on growth or value with quality often left out of the ...

  • InvestorPlace5 days ago

    Investors Need to Adopt a Different Mindset for Big Pharma and Biotech Stocks

    The ability to sell new drugs hinges on approvals from government bodies such as the Food and Drug Administration (FDA). As a result, biotech companies, and to some degree, large drug companies, go into business ventures without the certainty of ever earning revenues, let alone profits. Biotech stocks often become some of the most difficult to evaluate.

  • Why Is Johnson & Johnson (JNJ) Down 4.1% Since its Last Earnings Report?
    Zacks5 days ago

    Why Is Johnson & Johnson (JNJ) Down 4.1% Since its Last Earnings Report?

    Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Taking Stock of Gilead Sciences’ Key Developments
    Market Realist5 days ago

    Taking Stock of Gilead Sciences’ Key Developments

    During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.